COMMUNIQUÉS West-GlobeNewswire

-
Turn Therapeutics to Commence Trading Today on Nasdaq
08/10/2025 -
Ashvattha Therapeutics to Present Phase 2 DME and nAMD Data at Innovate Retina
08/10/2025 -
ARS Pharmaceuticals Receives Favorable Decision from European Patent Office on Patent Related to neffy® (epinephrine nasal spray)
08/10/2025 -
Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer
08/10/2025 -
MAPS and HoloMind Institute Host International MDMA-Assisted Therapy Training in Poland
08/10/2025 -
Izotropic Marks Breast Cancer Awareness Month by Highlighting Gaps in Care and the Need for IzoView Breast CT
08/10/2025 -
Vaxart to Showcase its Norovirus and COVID-19 Oral Pill Vaccine Candidates at World Vaccine Congress Europe 2025
08/10/2025 -
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08/10/2025 -
Starton Therapeutics to Share Innovative Lenalidomide Delivery Technology on Labroots Webinar Sponsored by Primetech Corporation
08/10/2025 -
Nasus Pharma Announces Expanded Agreement to Support Development and Commercialization of NS002 Intranasal Epinephrine Program
08/10/2025 -
Prenetics’ IM8 Launches Daily Ultimate Longevity, First Supplement to Target All 12 Hallmarks of Aging
08/10/2025 -
MaxCyte to Report Third Quarter 2025 Financial Results on November 5, 2025
08/10/2025 -
Evaxion expands AI-Immunology™ platform with automated vaccine design module
08/10/2025 -
Enovis completes sale of its Dr. Comfort Footcare Solutions business for proceeds of up to $60 million
08/10/2025 -
Science 37 Completes Third FDA Inspection, Validating Quality of its Direct-to-Patient Site in Pivotal Phase 3 Rare Disease Trial
08/10/2025 -
Gary Huff, Former CEO of LabCorp Diagnostics, Appointed to Biomerica Board of Directors
08/10/2025 -
Lisata Therapeutics and Catalent Announce Global Antibody-Drug Conjugate (ADC) License Agreement
08/10/2025 -
NurExone Demonstrates Reproducible, Dose-Dependent Vision Recovery in Preclinical Glaucoma Model
08/10/2025 -
Safety Shot Acquires 2.7% of BONK’s Circulating Supply, Sets Year-End Target of 5%
08/10/2025
Pages